Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Sep 26;134(13):1106-1109.
doi: 10.1182/blood.2019000795. Epub 2019 Jul 22.

Adjuvant Low-Dose Rituximab and Plasma Exchange for Acquired TTP

Affiliations
Free PMC article
Clinical Trial

Adjuvant Low-Dose Rituximab and Plasma Exchange for Acquired TTP

Jeffrey I Zwicker et al. Blood. .
Free PMC article

Conflict of interest statement

Conflict-of-interest disclosure: J.I.Z. discloses prior research funding from Quercegen Pharma and Incyte and has served on scientific advisory boards for Portola Pharmaceuticals, Bayer, Pfizer, and Seattle Genetics. J.M. and J.E.S. have a patent, fluorogenic substrate for ADAMTS‐13, US 8663912, issued to Washington University. The remaining authors declare no competing financial interests.

Similar articles

See all similar articles

Cited by 2 articles

Publication types

Supplementary concepts

LinkOut - more resources

Feedback